by GOT | Aug 24, 2021 | News
Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals NovaQuest Private Equity to support the continued growth of the combined innovative, patient-centric company WOBURN, MA & ATLANTA, GA (August 24, 2021) – Azurity Pharmaceuticals, Inc....
by GOT | Feb 8, 2021 | News
Azurity Pharmaceuticals Announces Three New Neurology Products WOBURN, Mass. (February 8, 2021) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care,...
by GOT | Aug 27, 2020 | Legacy Arbor Archives
Arbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin) for Patients with Central Precocious Puberty Company orders additional product amid reported industry shortage ATLANTA, Aug. 25, 2020 – Arbor Pharmaceuticals, LLC, a U.S.-based specialty...
by GOT | Jul 10, 2019 | News
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for...
by GOT | Apr 2, 2018 | CutisPharma Press Releases, News
CutisPharma Announces FIRVANQ™ WILMINGTON, Mass. (Apr. 2, 2018) – CutisPharma announced today the commercial launch of FIRVANQ ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by...
Recent Comments